Mobile

A Randomised, double blind, Placebo controlled, double dummy, parallel group, multicentre, dose ranging study in subjects with T2DM to evaluate the efficacy, safety, and tolerability of orally adminis...

Mise à jour : Il y a 5 ans
Référence : EUCTR2007-006693-28

A Randomised, double blind, Placebo controlled, double dummy, parallel group, multicentre, dose ranging study in subjects with T2DM to evaluate the efficacy, safety, and tolerability of orally administered SGLT2 inhibitor JNJ-28431754 with Sitagliptin as a reference arm

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective of this dose-ranging study is to evaluate the effects of JNJ-28431754 as compared with placebo on the change in hemoglobin A1c (A1C) from baseline to Week 12 in subjects with T2DM.

Critère d'inclusion

  • Patients with Type 2 Diabetes Mellitus (T2DM)

Liens